Company Profile

PIRAMAL ENTERPRISES LTD.

NSE : PELBSE : 500302ISIN CODE : INE140A01024Industry : Pharmaceuticals & DrugsHouse : Piramal Ajay
BSE936.30-2.5 (-0.27 % )
PREV CLOSE (Rs.) 938.80
OPEN PRICE (Rs.) 940.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 73438
TODAY'S LOW / HIGH (Rs.)909.50 949.95
52 WK LOW / HIGH (Rs.)608 2664.85
NSE936.50 -3 (-0.32 % )
PREV CLOSE(Rs.) 939.50
OPEN PRICE (Rs.) 938.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 2100980
TODAY'S LOW / HIGH(Rs.) 910.20 950.00
52 WK LOW / HIGH (Rs.)606.85 2666.04

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.01
Dividend Yield(%) 2.92
TTM EPS (Rs.) 25.33
P/E Ratio 36.96
Book Value (Rs.) 977.33
Face Value (Rs.) 2
MCap (Rs. in Mn) 211171.50
Price/Earning (TTM) 29.00
Price/Sales (TTM) 4.98
Price/Book (MRQ) 0.96
PAT Margin (%) -23.48
ROCE (%) 1.93
Incorporation Year : 1947

Management Info :

Ajay G Piramal - Chairman - Managing Director

Registered Office :

Address : Piramal Ananta Agastya Corporate Park ,Opposite Fire Brigade , Kamani Junction , L B S Marg ,Kurla ( W ),
Mumbai,
Maharashtra-400070

Phone : 022 3802 3000/4000

Website : www.piramal.com

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
NEWS More
16Mar03-16-2020$Piramal Enterprises informs about interest payment Piramal Enterprises informs

In compliance with Regulation 57 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Piramal Enterprises has informed that the company has made timely coupon payment for the Non-Convertible Debentures with, ISIN:INE140A07401,INEl40A07435 issued by the Company as on 16th March 2020.

The above information is a part of company’s filings submitted to BSE.

In compliance with Regulation 57 of SEBI (Listing Obligations a..
12Mar03-12-2020$Piramal Enterprises informs about analyst meet Piramal Enterprises informs

Piramal Enterprises has informed that pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the schedule of Analyst or Institutional Investor Meetings with the Company is on 12th March 2020 with Morgan Stanley India at Mumbai.

The above information is a part of company’s filings submitted to BSE.








Piramal Enterprises has informed that pursuant to Regulation 30..
06Mar03-06-2020$Piramal Enterprises informs about loss of share certificate Piramal Enterprises informs

Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Piramal Enterprises has informed that the Registrar and Transfer Agent (RTA) of the Company Link Intime India has received requests for issuance of duplicate share certificates from the Shareholder, Shashi Khanchandani (SS00569). The duplicate share certificates will be issued only after the receipt of all necessary document from the Shareholder.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 39(3) of the SEBI (Listing Obligations a..
04Mar03-04-2020$Piramal Enterprises informs about record dates for NCDs Piramal Enterprises informs

Pursuant to Regulation 60 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Piramal Enterprises has informed that the record dates for the Non-Convertible Debentures (NCDs) (INE140A07401, INE140A07435, and INE140A07567) issued by the Company, is on 8th & 16th April 2020.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 60 of the SEBI (Listing Obligations and..
02Mar03-02-2020$Piramal Enterprises receives Rs 6,500 crore on closing sale of DRG business Piramal Enterprises receives

Piramal Enterprises has received $900 million (around Rs 6,500 crore) on completion of divestment of stake in its healthcare insights and analytics business to US-headquartered Clarivate Analytics. In January 2020, the company had signed an agreement for sale of its Decision Resources Group (DRG) business to Clarivate Analytics for $950 million. The company would use the money to reduce debt and to explore organic and inorganic growth opportunities.

Piramal Enterprises is one of India’s large diversified companies, with a presence in Pharmaceuticals, Healthcare Information Management and Financial Services.

Piramal Enterprises has received $900 million (around Rs 6,500..
Financials More
Rs. in Millions
QTR Dec 19 ANNUAL 19
Net Profit367.200000000001-8619.8
Gross Profit 1127 -7915.8
Operating Profit 5307.421241.7
Net Sales 9156.736714
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Sanofi India (BSE)
 6483.75 (3.87%)
M.Cap ( in Cr)
14932.48
Abbott India (BSE)
 15639.50 (1.19%)
M.Cap ( in Cr)
33232.85
Hester Biosciences (BSE)
 951.70 (2.88%)
M.Cap ( in Cr)
809.60
Procter&Gamble Healt (BSE)
 3669.75 (0.69%)
M.Cap ( in Cr)
6091.56
NGL Fine-Chem (BSE)
 274.45 (8.33%)
M.Cap ( in Cr)
169.56
Shareholding Pattern More
FI/BANKS/INSURANCE 8.81 %
PROMOTERS 46.06 %
NON-INSTITUTION 14.99 %
MUTUAL FUNDS/UTI 0.42 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes